T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$3.45B |
| 2 |
Pinterest
PINS
|
+$1.89B |
| 3 |
T-Mobile US
TMUS
|
+$1.89B |
| 4 |
Zoom
ZM
|
+$1.77B |
| 5 |
UiPath
PATH
|
+$1.71B |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alibaba
BABA
|
+$3.66B |
| 2 |
Caterpillar
CAT
|
+$1.32B |
| 3 |
Netflix
NFLX
|
+$1.18B |
| 4 |
MXIM
Maxim Integrated Products
MXIM
|
+$1.15B |
| 5 |
Micron Technology
MU
|
+$1.07B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 24.62% |
| 2 | Healthcare | 16.07% |
| 3 | Consumer Discretionary | 15.29% |
| 4 | Communication Services | 13.46% |
| 5 | Financials | 12.46% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1201
Senti Biosciences Holdings
SNTI
$12M
| $29.8M | ﹤0.01% |
+300,000
| New | +$29.9M |
|
1202
Royal Caribbean
RCL
$82.4B
| $29.6M | ﹤0.01% |
347,499
-2,490
| -0.7% | -$217K |
|
1203
Annexon
ANNX
$873M
| $29.5M | ﹤0.01% |
1,310,484
-28,877
| -2% | -$640K |
|
|
SPNS
1204
DELISTED
Sapiens International
SPNS
| $29.1M | ﹤0.01% |
1,108,776
-148
| -0% | -$4.37K |
|
|
PCSB
1205
DELISTED
PCSB Financial Corporation
PCSB
| $29.1M | ﹤0.01% |
1,601,725
-10,480
| -0.7% | -$187K |
|
1206
NetApp
NTAP
$39.6B
| $28.8M | ﹤0.01% |
351,729
-12,890
| -4% | -$1.01M |
|
1207
Douglas Dynamics
PLOW
$981M
| $28.6M | ﹤0.01% |
703,883
-66,837
| -9% | -$2.93M |
|
|
AKRO
1208
DELISTED
Akero Therapeutics
AKRO
| $28.6M | ﹤0.01% |
1,154,203
+261,057
| +29% | +$7.33M |
|
1209
Amcor
AMCR
$21.5B
| $28.6M | ﹤0.01% |
498,926
-10,402
| -2% | -$619K |
|
1210
Genuine Parts
GPC
$18.5B
| $28.4M | ﹤0.01% |
224,654
-7,790
| -3% | -$980K |
|
1211
Cincinnati Financial
CINF
$26.5B
| $28.4M | ﹤0.01% |
243,557
-5,090
| -2% | -$588K |
|
1212
FS Bancorp
FSBW
$325M
| $28.3M | ﹤0.01% |
794,806
-564
| -0.1% | -$19.5K |
|
1213
Healthpeak Properties
DOC
$14.2B
| $28.3M | ﹤0.01% |
850,596
-12,590
| -1% | -$423K |
|
1214
Kimbell Royalty Partners
KRP
$1.53B
| $28.3M | ﹤0.01% |
2,203,325
-208,630
| -9% | -$2.49M |
|
|
NARI
1215
DELISTED
Inari Medical, Inc. Common Stock
NARI
| $28.2M | ﹤0.01% |
302,766
-269,128
| -47% | -$26.1M |
|
1216
Design Therapeutics
DSGN
$917M
| $28.2M | ﹤0.01% |
1,448,968
+13,714
| +1% | +$346K |
|
1217
Innovative Industrial Properties
IIPR
$1.67B
| $28.1M | ﹤0.01% |
147,161
+3,106
| +2% | +$570K |
|
1218
Mercury Systems
MRCY
$6.7B
| $28.1M | ﹤0.01% |
423,395
-19,589
| -4% | -$1.35M |
|
|
SAND
1219
DELISTED
Sandstorm Gold
SAND
| $27.8M | ﹤0.01% |
3,523,384
+3,348,356
| +1,913% | +$27.1M |
|
1220
Viatris
VTRS
$18.5B
| $27.6M | ﹤0.01% |
1,933,067
-15,509
| -0.8% | -$224K |
|
1221
Aaon
AAON
$7.03B
| $27.5M | ﹤0.01% |
659,039
-41,029
| -6% | -$1.81M |
|
1222
IDEAYA Biosciences
IDYA
$3.56B
| $27.5M | ﹤0.01% |
1,309,977
+409,712
| +46% | +$8.42M |
|
|
PVBC
1223
DELISTED
Provident Bancorp
PVBC
| $27.4M | ﹤0.01% |
1,680,131
-1,060
| -0.1% | -$17.1K |
|
|
AXNX
1224
DELISTED
Axonics, Inc. Common Stock
AXNX
| $27.4M | ﹤0.01% |
431,353
-29,111
| -6% | -$1.72M |
|
1225
Seagate
STX
$209B
| $27.3M | ﹤0.01% |
311,018
-12,000
| -4% | -$1.08M |
|
Similar funds
T. Rowe Price Associates's Q2 2021 Portfolio in Review
As of Q2 2021, T. Rowe Price Associates held 3,000 positions worth $1.08T, up 8% from $999B the previous quarter. Its ten largest holdings account for 26% of the portfolio.
T. Rowe Price Associates's Q2 2021 filing shows 159 new, 1,164 increased, 1,499 reduced and 84 closed positions. Its largest new stake was UiPath: 23,377,090 shares worth $1.52B. The largest sale was Alibaba, an estimated $3.66B.
By sector, the portfolio is most concentrated in Technology at 25% of assets, up from 23% a quarter earlier, followed by Healthcare and Consumer Discretionary.
- T. Rowe Price Associates's largest Q2 2021 buy was UiPath: 23,377,090 shares worth $1.52B.
- T. Rowe Price Associates added most to Microsoft in Q2 2021, an estimated $3.45B increase.
- T. Rowe Price Associates's biggest Q2 2021 reduction was Alibaba, cutting an estimated $3.66B.
- T. Rowe Price Associates fully exited Pershing Square Tontine Holdings, Ltd. in Q2 2021, selling an estimated $145M.
- T. Rowe Price Associates's ten largest holdings make up 26% of its $1.08T portfolio in Q2 2021.
- T. Rowe Price Associates opened 159 new positions and closed 84 in Q2 2021.
- T. Rowe Price Associates's portfolio value rose 8% quarter-over-quarter to $1.08T.
Based on T. Rowe Price Associates's 13F filing for Q2 2021, filed 16 Aug 2021.